2025-10-20T12:01:23-05:00 2024-12-31 HAN GROUP LLC 1020 19TH STREET NW SUITE 800 WASHINGTON DC 20036 990 2024-01-01 522029668 INSTITUTE FOR IN VITRO SCIENCES INC INST 3019476523 30 W WATKINS MILL ROAD 100 GAITHERSBURG MD 20878 AMANDA K ULREY PRESIDENT 3019476523 2025-10-20 1 1 JENNIFER S HAN P00633304 2022937000 2025-10-10 2024 2025-03-06 01:10:19Z AMANDA K ULREY 30 W WATKINS MILL ROAD 100 GAITHERSBURG MD 20878 7953184 0 X IIVS.ORG X 1997 MD TO INCREASE THE USE AND ACCEPTANCE OF NON-ANIMAL TEST METHODS WORLDWIDE. 8 5 58 5 0 0 1057602 841058 5815193 7072432 5121 5162 65 34532 6877981 7953184 0 0 0 0 4503165 4587753 0 0 19337 2662471 3348045 7165636 7935798 -287655 17386 6152852 5925753 3810965 3566480 2341887 2359273 X THE MISSION OF THE INSTITUTE FOR IN VITRO SCIENCES (IIVS) IS TO DRIVE THE OPTIMIZATION AND APPLICATION OF SCIENTIFICALLY ROBUST IN VITRO METHODS THAT ARE ACCEPTED BY REGULATORY AGENCIES AND ADOPTED BY INDUSTRY WORLDWIDE. TO CREATE A FORUM IN WHICH INDUSTRY, REGULATORY AGENCIES AND ANIMAL WELFARE ORGANIZATIONS CAN WORK TOGETHER TO DEVELOP HUMANE SCIENTIFIC TOOLS FOR TESTING. TO UTILIZE OUR EXPERTISE TO CREATE EDUCATIONAL AND OUTREACH PROGRAMS THAT WILL EXPAND THE ADOPTION OF NON-ANIMAL TEST METHODS AROUND THE GLOBE. 0 0 6599135 6969745 RESEARCH AND TESTING: IIVS WORKED WITH MORE THAN SIXTY COMPANIES TO DETERMINE THE APPROPRIATE NON-ANIMAL TESTING STRATEGIES, CONDUCT TESTING, AND ASSIST IN INTERPRETATION OF DATA. OVER 880 COMPOUNDS/PRODUCTS WERE TESTED AT THE IIVS LABORATORY - MOSTLY IN MORE THAN ONE TEST. IIVS CONTINUES TO OPTIMIZE AND STANDARDIZE IN VITRO METHODS TO MAKE THEM SUITABLE FOR INDUSTRY AND REGULATORY NEEDS. MANY OF THESE EFFORTS ARE IN COLLABORATION WITH STAKEHOLDERS SUCH AS INDUSTRY, GOVERNMENT AND NGOS. ADVANCEMENTS ARE SHARED WITH THE SCIENTIFIC COMMUNITY THROUGH PRESENTATIONS AND PUBLICATIONS SO THAT OTHER INDUSTRIES AND REGULATORY SCIENTISTS CAN BENEFIT. IIVS HAS DEVELOPED AND PROMOTED THE USE OF HUMAN PRECISION CUT LUNG SLICES (HPCLS FOR POTENTIAL REGULATORY APPLICATION AS AN ALTERNATIVE TO USING ANIMALS FOR INHALATION AND RESPIRATORY ENDPOINTS. BASED UPON OUR SUCCESSFUL USE OF HPCLS IN IN-HOUSE STUDIES, STAKEHOLDERS HAVE INQUIRED WHETHER THEY COULD PROCURE THESE HPCLS TISSUES FOR USE WITHIN THEIR OWN LABORATORIES. IIVS PREPARED AND QUALIFIED HPCLS TISSUES FOR 30 SPONSOR-RUN LABORATORY STUDIES THAT WOULD HAVE OTHERWISE USED ANIMALS. 874848 102687 EDUCATION AND OUTREACH: IIVS PARTICIPATES IN NUMEROUS TRAINING ACTIVITIES FOR A VARIETY OF STAKEHOLDERS INCLUDING INDUSTRY AND REGULATORY SCIENTISTS. THESE TRAININGS ARE TAILORED FOR THE SPECIFIC AUDIENCE AND GENERALLY INCLUDE LECTURES, HANDS-ON DEMONSTRATIONS AND DATA INTERPRETATION. TWO MAJOR PROGRAMS IN WHICH IIVS PARTICIPATES ARE THE PHYSICIANS COMMITTEE FOR RESPONSIBLE MEDICINE NURA TRAINING AND THE ANIMAL FREE SAFETY ASSESSMENT COLLABORATION COORDINATED BY HUMANE SOCIETY INTERNATIONAL. IIVS SCIENTISTS WERE INVITED TO PARTICIPATE IN EXPERT PANELS CONVENED BY THE ORGANIZATION FOR ECONOMIC COOPERATION AND DEVELOPMENT (OECD) WHICH HARMONIZES IN VITRO TESTING APPROACHES FOR THE WORLDWIDE SCIENTIFIC COMMUNITY. THESE PANELS DISCUSSED NEW METHODS FOR GENETIC TOXICOLOGY, SKIN SENSITIZATION, EYE IRRITATION AND SKIN CORROSION. IIVS IS LEADING EFFORTS WITH INDUSTRY CONSORTIA AND 2 DIVISIONS OF THE US FEDERAL DRUG ADMINISTRATION TO APPLY NON-ANIMAL METHODS FOR SPECIFIC ENDPOINTS. IIVS IS ALSO INVOLVED IN EFFORTS TO SUPPORT THE US ENVIRONMENTAL PROTECTION AGENCY'S GOAL TO REDUCE RELIANCE ON ANIMAL MODELS. IIVS STAFF HOLD BOARD POSITIONS WITHIN SOCIETIES THAT HAVE THE MISSION TO WORK COLLABORATIVELY TO INCREASE THE USE AND ACCEPTANCE OF ALTERNATIVE METHODS, SUCH AS THE AMERICAN SOCIETY FOR CELLULAR AND COMPUTATIONAL TOXICOLOGY, THE EUROPEAN SOCIETY FOR TOXICOLOGY IN VITRO, THE US SOCIETY OF TOXICOLOGY AND THE CHINESE SOCIETY OF TOXICOLOGY. 7473983 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 10 0 1 58 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 5 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA MD NJ NY OH OR PA TN VA WI X HANS A RAABE 3019476523 30 W WATKINS MILL ROAD 100 GAITHERSBURG MD 20878 AMANDA K ULREY PRESIDENT 40.00 X X 155148 0 8722 HANS A RAABE CHIEF OPERATING OFFICER/TREASURER 40.00 X X 148071 0 17733 RODGER D CURREN CEO/BOARD CHAIR/SECRETARY 10.00 X X 20962 0 838 DANIEL A BAGLEY DIRECTOR 0.50 X 0 0 0 JOHN R FOWLE DIRECTOR 0.50 X 0 0 0 A WALLACE HAYES DIRECTOR 0.50 X 0 0 0 JAMES M HOFFMAN DIRECTOR 0.50 X 0 0 0 RICHARD E KOURI DIRECTOR 0.50 X 0 0 0 HOLGER P BEHRSING DIRECTOR RESPIRATORY TOXICOLOGY 40.00 X 161185 0 14748 GERTRUDE-EMILIA COSTIN DIRECTOR OF LABORATORY SERVICES 40.00 X 150051 0 11298 ALLISON M HILBERER TOXICOLOGIST II/STUDY DIRECTOR 40.00 X 120182 0 13112 NATHAN R WILT STUDY DIRECTOR 40.00 X 118662 0 13305 KRISTIE M SULLIVAN VP, EDUCATION AND OUTREACH 40.00 X 114604 0 6845 988865 0 86601 11 0 1 0 0 40082 800976 841058 RESEARCH AND TESTING 541700 6969745 6969745 EDUCATIONAL ACTIVITIES 611710 102687 102687 7072432 5162 5162 REIMBURSEMENTS 900099 33503 33503 HONORARIUM 900099 1029 1029 34532 7953184 7072432 0 39694 351474 272635 76983 1856 3496865 3306231 181543 9091 100434 97550 2683 201 344069 328475 14788 806 294911 279640 14568 703 11969 11969 74471 74471 32814 32289 519 6 20365 20365 56662 54905 1667 90 192558 179045 13241 272 5702 5702 531077 503572 26234 1271 171074 165719 2707 2648 17418 16485 933 19738 19164 547 27 245792 234686 10594 512 92910 74176 18545 189 LABORATORY EXPENSES 1862294 1862294 DUES/MEMBERSHIPS/PUBS. 6002 4296 41 1665 LICENSE FEES & PERMITS 5199 4785 414 BAD DEBT EXPENSE 2000 2000 7935798 7473983 442478 19337 11393 71138 543171 648096 50003 107162 1701761 1851300 124103 126073 2511735 1639324 1050597 872411 2671824 2249573 6152852 5925753 446846 570660 207001 215975 95253 161716 3061865 2618129 3810965 3566480 X 2306887 2334273 35000 25000 2341887 2359273 6152852 5925753 17386 0 X X 0 1 X 1 0 X 944137 1949651 1077048 1057602 841058 5869496 4935016 4553806 5782738 5815193 7072432 28159185 5879153 6503457 6859786 6872795 7913490 34028681 695000 964511 675000 704400 441600 3480511 2744479 1417195 2775189 2621254 2658623 12216740 3439479 2381706 3450189 3325654 3100223 15697251 18331430 13 440 5609 5162 11224 13 440 5609 5162 11224 897 65 1029 1991 5879153 6503470 6861123 6878469 7919681 34041896 0.53850 0.61420 0.00030 0.00020 X SCHEDULE A, PART III, LINE 12, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2020 AMOUNT: $ 0. 2021 AMOUNT: $ 0. 2022 AMOUNT: $ 897. 2023 AMOUNT: $ 65. 2024 AMOUNT: $ 0. HONORARIUM - 2020 AMOUNT: $ 0. 2021 AMOUNT: $ 0. 2022 AMOUNT: $ 0. 2023 AMOUNT: $ 0. 2024 AMOUNT: $ 1,029. PART III, DESCRIPTION OF THE UPDATED NUMBERS THE FOLLOWING REVENUE AMOUNTS ON SCHEDULE A, PART III HAVE BEEN UPDATED FROM PRIOR 990S IN ORDER TO ACCURATELY REFLECT REVENUE AMOUNTS FROM THEIR RESPECTIVE YEARS. PART III, LINE 10A, COLUMN(A), 2020 PART III, LINE 7B, COLUMN(A), 2020 PART III, LINE 7B, COLUMN(B), 2021 PART III, LINE 7B, COLUMN(C), 2022 PART III, LINE 7B, COLUMN(D), 2023 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 851097 536485 314612 43730 43730 1616908 1102839 514069 872411 DEPOSITS 27425 OPERATING LEASE RIGHT-OF-USE ASSET, NET 2120514 FINANCING LEASE RIGHT-OF-USE ASSET, NET 101634 2249573 RIGHT-OF-USE OPERATING LEASE LIABILITY 2516495 RIGHT-OF-USE FINANCING LEASE LIABILITY 101634 2618129 X 7953184 0 7953184 0 7953184 7935798 0 7935798 0 7935798 PART X, LINE 2: THE INSTITUTE IS GENERALLY EXEMPT FROM FEDERAL INCOME TAXES UNDER THE PROVISIONS OF SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND IS NOT CONSIDERED TO BE A PRIVATE FOUNDATION. UNDER CURRENT INTERNAL REVENUE SERVICE REGULATIONS, REVENUE FROM CERTAIN UNRELATED BUSINESS ACTIVITIES IS SUBJECT TO UNRELATED BUSINESS INCOME TAX. THE INSTITUTE HAD NO NET INCOME TAX EXPENSE ON UNRELATED BUSINESS INCOME FOR THE YEAR ENDED DECEMBER 31, 2024. ACCORDINGLY, NO PROVISION FOR INCOME TAXES HAS BEEN MADE ON THE ACCOMPANYING FINANCIAL STATEMENTS. MANAGEMENT EVALUATED THE INSTITUTE'S TAX POSITIONS AND CONCLUDED THAT THE INSTITUTE HAD TAKEN NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS TO COMPLY WITH THE PROVISIONS OF THIS GUIDANCE. EAST ASIA AND THE PACIFIC 0 2 PROGRAM SERVICES REGULATORY OUTREACH AND TRAINING 54675 EUROPE (INCLUDING ICELAND & GREENLAND) 0 2 PROGRAM SERVICES IN VITRO LABORATORY QUALITY EFFORTS AND OUTREACH 23407 SOUTH AMERICA 0 2 PROGRAM SERVICES HANDS-ON TRAINING IN NAMS 9612 NORTH AMERICA 0 1 PROGRAM SERVICES TRAINING ON EYE IRRATION TEST METHODS 1072 SOUTH ASIA 0 2 PROGRAM SERVICES ESTABLISHING CONNECTIONS FOR FUTURE TRAINING OPPORTUNITIES 981 0 9 0 0 0 9 89747 0 89747 0 0 0 0 0 0 PART I, LINE 3: IN ACCORDANCE WITH IRS INSTRUCTIONS, ALL AMOUNTS REPORTED IN PART I OF SCHEDULE F ARE REPORTED USING THE ACCRUAL BASIS OF ACCOUNTING, WHICH IS THE SAME METHOD OF ACCOUNTING USED IN THE FINANCIAL STATEMENTS. X X X 0 0 0 0 0 0 0 0 0 HOLGER P BEHRSING DIRECTOR RESPIRATORY TOXICOLOGY 160840 0 0 0 345 0 6434 0 8314 0 175933 0 0 0 HANS A RAABE CHIEF OPERATING OFFICER/TREASURER 147081 0 0 0 990 0 6435 0 11298 0 165804 0 0 0 AMANDA K ULREY PRESIDENT 154923 0 0 0 225 0 6197 0 2525 0 163870 0 0 0 GERTRUDE-EMILIA COSTIN DIRECTOR OF LABORATORY SERVICES 149706 0 0 0 345 0 0 0 11298 0 161349 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 QUESTIONNAIRE FROM THE INDEPENDENT TAX CONSULTING FIRM IS FILLED OUT BY THE PRESIDENT, THE CHIEF OPERATING OFFICER AND THE CONTROLLER OF THE CORPORATION. WHEN THE COMPLETED FORM 990 IS RECEIVED FROM THE INDEPENDENT TAX CONSULTING FIRM, IT IS REVIEWED BY ALL THREE OF THE OFFICERS OF THE CORPORATION DURING A MEETING RUN BY THE PRESIDENT. ANY DISCREPANCIES ARE REVIEWED AND ADDRESSED WITH THE INDEPENDENT TAX CONSULTANT. THE FINAL FORM 990 IS SENT TO ALL BOARD MEMBERS BEFORE SUBMISSION TO THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS REVIEWED AT THE ANNUAL MEETING OF THE BOARD OF DIRECTORS BY THE CHAIRMAN OF THE BOARD OF DIRECTORS. EACH MEMBER IS ASKED IF ANY NEW CONFLICT OF INTERESTS HAVE OCCURRED. IF A POTENTIAL CONFLICT IS UNCOVERED, A SOLUTION IS PROPOSED AND VOTED ON BY MEMBERS OF THE BOARD OF DIRECTORS AND RECORDED IN THE OFFICIAL MINUTES. EACH OF THESE ISSUES IS REVIEWED AT THE ANNUAL MEETING OF THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 15 DATA ON COMPARABLE SALARIES WITHIN PROFIT AND NONPROFIT ENTITIES IS COLLECTED FROM VARIOUS SOURCES THROUGHOUT THE YEAR, INCLUDING SURVEYS FROM APPROPRIATE TRADE JOURNALS OR MAGAZINES, PERSONAL CONTACT WITH HUMAN RESOURCE DEPARTMENTS AND ONLINE DATABASES. THIS DATA IS BROUGHT TO A MEETING OF THE BOARD OF DIRECTORS FOR REVIEW AND DISCUSSION IN CORRELATION WITH THE CORPORATION'S REVENUES AND EXPENSES. THE CEO SUGGESTS AN INCREASE IN SALARY FOR EACH OFFICER, AND AN OFFICER OR INDEPENDENT BOARD MEMBER SUGGESTS AN INCREASE IN SALARY FOR THE CEO. AFTER DISCUSSION AND COMMENTS, THE INCREASES FOR EACH OFFICER ARE VOTED UPON FOR APPROVAL. THE PROCESS WAS LAST CONDUCTED IN JANUARY 2025. FORM 990, PART VI, SECTION C, LINE 19 IIVS MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC IN TWO WAYS: 1) REQUESTS CAN BE MADE BY PHONE OR EMAIL; 2) DOCUMENTS ARE AVAILABLE FOR INSPECTION AND COPYING ON-SITE AT IIVS' FACILITIES. THESE DOCUMENTS ARE AVAILABLE FOR THE SAME PERIOD OF DISCLOSURE AS SET FORTH IN SECTION 6104(D). FORM 990, PART XII, LINE 2C: THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.